MS
EUCRU

Maven Securities’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Maven Securities’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,091
Closed -$331K – 1434
2021
Q1 		$331K Sell
33,091
-16,909
-34% -$180K 0.01% 780
2020
Q4 		$533K Buy
+50,000
New +$508K 0.05% 347

Other funds holding EUCRU

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Maven Securities's EUCRU Position: Q2 2021 in Review

Maven Securities sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q2 2021, closing a stake of 33,091 shares — an estimated $331K sold.

Maven Securities first reported a position in EUCRU in Q4 2020 and held it in 2 quarters. The position peaked at $533K in Q4 2020. 19 funds tracked by Wall St. Rank hold EUCRU as of Q2 2021.

  • Maven Securities reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 33,091 Eucrates Biomedical Acquisition Corp. Unit shares in Q2 2021, an estimated $331K.
  • Maven Securities first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Eucrates Biomedical Acquisition Corp. Unit position peaked at $533K in Q4 2020.
  • 19 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.